+91 - 830 - 3146878
The purpose of this study was to evaluvate the efficacy of new herbomineral drug of LAS02 in Bone cancer patients who admitted in Lavanya Ayurvedic Hospital & Research Centre For Cancer and AIDS. The study was conducted after getting ethical clearance. Total 19 patients were enrolled in Lavanaya hospital. These patients were suffering only from Bone cancer not any other diseases. All patients having medication ayuredic herbomineral drug of LAS02 for more than one month treatment. After obtaining prior consent form these patients, venous blood samples was collected from the subjects before and after treatment with herbomineral drug of LAS02 and measured the hematological and biochemical examinations along with Bone cancer in total Bone size.
A 52.57% percentage reduction of total Bone size (mm) in bone cancer treated patients as compared to before treated patients (n=19) A percentages decrease of (6.06% ) ESR levels in patients after treatment with LAS02 more than one month as compared with before treatment. There were significant reduction of hepatic enzymes (SGOT, SGPT, ALP and LDH) levels in patients treated with LAS02 drug in comparison to before treatment . On the basis of these examinations, we say that LAS 02 is most effective herbomineral drug for the management of Bone cancer.
The study was conducted after getting ethical clearance from Institutional human ethic committee. Total 19 Bone cancer patients with age (02-70 years) in Lavanya Ayurvedic Hospital and Research Center. These patients were only suffering from bone cancer patients not from any organic diseases. After obtaining prior consent form, venous blood samples was collected from the subjects before (pre) and after treatment (post) with herbomineral drug LAS02 Capsule under aseptic condition. The drug was given to these patients for two months. After collection of blood sample, serum and plasma were separated by centrifugation at 4000 rpm for 10 min. at room temperature for measurement of hematological, biochemical parameters along with in pre and post treated patients.
All hematological and biochemistry parameters hemoglobin (Hb), erythrocyte sedimentation rate (ESR), lactate dehydragenase (LDH) alkaline phosphate (ALP), Serum glutamate oxaloacetate transminase (SGOT), Serum glutamate pyurvate transminase (SGPT) were measured by fully automatic cell counter and clinical chemistry analyzer.
LDH activity was measured by kit according to protocol provided by supplier (Transasia biomedical). The activity was expressed as an IU/ml.
Resulting data were expressed mean ± SD. Percentage parenthesis was observed between pre vs post treated patients with LAS02 drug in bone cancer.
There was reduction of 52.57% total Bone tumor Size (mm) in Bone cancer post treated patients as compared with pre treated patients.
SGOT and SGPT level was significantly decreased in treated patients. after treatment with drug LAS02 in comparison to pre treatment.
ESR level was significantly decreased 1.79% in patients after treatment with drug LAS02 in comparison to pre treatment.
RBC and platelets level was significantly decreased 5.68%, 14.92% in patients after treatment with drug LAS02 in comparison to pre treatment. This parameter was found within normal range.
There were slightly increased Hb(%), hematocrit levels in patient treated group as compared with patient pre treated group.
The ALP level was significantly decreased 39.01% in the patients after treatment with drug LAS02 in comparison to pre treatment.
On the basis of these findings it is suggested that the herbomineral drug LAS02 is most effective medicine for prevention of Bone cancer.
The purpose of this study was to evaluate the acute oral toxicity study of LAS02 in female Sprague Dawley rat model. [...]
The purpose of this study was to evaluate the maximum tolerated dose of LAS02 in Sprague dawley female rat. [...]
The aim of this study was to evaluate the maximum tolerated dose of LAS02 in female Sprague Dawley rat. [...]